Menu
×
West Ashley Library
Closed
Phone: (843) 766-6635
Folly Beach Library
Closed
Phone: (843) 588-2001
Edgar Allan Poe/Sullivan's Island Library
Closed for renovations
Phone: (843) 883-3914
Wando Mount Pleasant Library
Closed
Phone: (843) 805-6888
Village Library
Closed
Phone: (843) 884-9741
St. Paul's/Hollywood Library
Closed
Phone: (843) 889-3300
Otranto Road Library
Closed
Phone: (843) 572-4094
Mt. Pleasant Library
Closed
Phone: (843) 849-6161
McClellanville Library
Closed
Phone: (843) 887-3699
Keith Summey North Charleston Library
Closed
Phone: (843) 744-2489
John's Island Library
Closed
Phone: (843) 559-1945
Hurd/St. Andrews Library
Closed
Phone: (843) 766-2546
Miss Jane's Building (Edisto Library Temporary Location)
Closed
Phone: (843) 869-2355
Dorchester Road Library
Closed
Phone: (843) 552-6466
John L. Dart Library
Closed
Phone: (843) 722-7550
Baxter-Patrick James Island
Closed
Phone: (843) 795-6679
Main Library
2 p.m. – 5 p.m.
Phone: (843) 805-6930
Bees Ferry West Ashley Library
Closed
Phone: (843) 805-6892
Mobile Library
Closed
Phone: (843) 805-6909
Today's Hours
West Ashley Library
Closed
Phone: (843) 766-6635
Folly Beach Library
Closed
Phone: (843) 588-2001
Edgar Allan Poe/Sullivan's Island Library
Closed for renovations
Phone: (843) 883-3914
Wando Mount Pleasant Library
Closed
Phone: (843) 805-6888
Village Library
Closed
Phone: (843) 884-9741
St. Paul's/Hollywood Library
Closed
Phone: (843) 889-3300
Otranto Road Library
Closed
Phone: (843) 572-4094
Mt. Pleasant Library
Closed
Phone: (843) 849-6161
McClellanville Library
Closed
Phone: (843) 887-3699
Keith Summey North Charleston Library
Closed
Phone: (843) 744-2489
John's Island Library
Closed
Phone: (843) 559-1945
Hurd/St. Andrews Library
Closed
Phone: (843) 766-2546
Miss Jane's Building (Edisto Library Temporary Location)
Closed
Phone: (843) 869-2355
Dorchester Road Library
Closed
Phone: (843) 552-6466
John L. Dart Library
Closed
Phone: (843) 722-7550
Baxter-Patrick James Island
Closed
Phone: (843) 795-6679
Main Library
2 p.m. – 5 p.m.
Phone: (843) 805-6930
Bees Ferry West Ashley Library
Closed
Phone: (843) 805-6892
Mobile Library
Closed
Phone: (843) 805-6909
Patron Login
menu
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
- Author(s): Muñoz-Gómez MJ;Muñoz-Gómez MJ; Ryan P; Ryan P; Ryan P; Ryan P; Ryan P; Quero-Delgado M; Quero-Delgado M; Martin-Vicente M; Martin-Vicente M; Cuevas G; Cuevas G; Valencia J; Valencia J; Valencia J; Jiménez E; Jiménez E; Jiménez E; Blanca-López N; Blanca-López N; Lara-Álvarez MÁ; Lara-Álvarez MÁ; Lara-Álvarez MÁ; Hernández-Rivas JÁ; Hernández-Rivas JÁ; Hernández-Rivas JÁ; Redondo G; Redondo G; Mas V; Mas V; Sepúlveda-Crespo D; Sepúlveda-Crespo D; Sepúlveda-Crespo D; Vázquez M; Vázquez M; Torres-Macho J; Torres-Macho J; Torres-Macho J; Martínez I; Martínez I; Martínez I; Resino S; Resino S; Resino S
- Source:
Journal of infection and public health [J Infect Public Health] 2024 Jul; Vol. 17 (7), pp. 102473. Date of Electronic Publication: 2024 Jun 07.- Publication Type:
Journal Article- Language:
English - Source:
- Additional Information
- Source: Publisher: Elsevier Country of Publication: England NLM ID: 101487384 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1876-035X (Electronic) Linking ISSN: 18760341 NLM ISO Abbreviation: J Infect Public Health Subsets: MEDLINE
- Publication Information: Original Publication: Oxford : Elsevier, 2008-
- Subject Terms: COVID-19*/immunology ; COVID-19*/prevention & control ; COVID-19 Vaccines*/immunology ; COVID-19 Vaccines*/administration & dosage ; Spike Glycoprotein, Coronavirus*/immunology ; SARS-CoV-2*/immunology ; Neoplasms*/immunology ; Antibodies, Viral*/blood; Humans ; Prospective Studies ; Male ; Female ; Middle Aged ; Aged ; T-Lymphocytes/immunology ; Immunization, Secondary ; Vaccination ; Adult ; Immunity, Humoral ; Immunoglobulin G/blood ; Immunocompromised Host ; Immunity, Cellular
- Abstract: Background: Cancer patients often have weakened immune systems, resulting in a lower response to vaccines, especially those receiving immunosuppressive oncological treatment (OT). We aimed to assess the impact of OT on the humoral and T-cell response to the B.1 lineage and Omicron variant following COVID-19 vaccination in patients with solid and hematological neoplasms.
Methods: We conducted a prospective study on cancer patients, stratified into OT and non-OT groups, who received a two-dose series of the COVID-19 mRNA vaccine and a booster six months later. The outcomes measured were the humoral (anti-SARS-CoV-2 S IgG titers and ACE2-S interaction inhibition capacity) and cellular (SARS-CoV-2 S-specific T-cell spots per million PBMCs) responses against the B.1 lineage and Omicron variant. These responses were evaluated four weeks after the second dose (n = 98) and eight weeks after the booster dose (n = 71).
Results: The humoral response after the second vaccine dose against the B.1 lineage and Omicron variant was significantly weaker in the OT group compared to the non-OT group (q-value<0.05). A booster dose of the mRNA-1273 vaccine significantly improved the humoral response in the OT group, making it comparable to the non-OT group. The mRNA-1273 vaccine, designed for the original Wuhan strain, elicited a weaker humoral response against the Omicron variant compared to the B.1 lineage, regardless of oncological treatment or vaccine dose. In contrast, T-cell responses against SARS-CoV-2, including the Omicron variant, were already present after the second vaccine dose and were not significantly affected by oncological treatments.
Conclusions: Cancer patients, particularly those receiving immunosuppressive oncological treatments, should require booster doses and adapted COVID-19 vaccines for new SARS-CoV-2 variants like Omicron. Future studies should evaluate the durability of the immune response and the efficacy of individualized regimens.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.) - Contributed Indexing: Keywords: B.1 lineage; COVID-19 vaccine; Immune response; Omicron variant; SARS-CoV-2
- Accession Number: 0 (COVID-19 Vaccines)
0 (Spike Glycoprotein, Coronavirus)
0 (Antibodies, Viral)
0 (spike protein, SARS-CoV-2)
0 (Immunoglobulin G) - Subject Terms: SARS-CoV-2 variants
- Publication Date: Date Created: 20240612 Date Completed: 20240620 Latest Revision: 20240620
- Publication Date: 20240621
- Accession Number: 10.1016/j.jiph.2024.102473
- Accession Number: 38865774
- Source:
Contact CCPL
Copyright 2022 Charleston County Public Library Powered By EBSCO Stacks 3.3.0 [350.3] | Staff Login
No Comments.